此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Safety, Tolerability, and Immunogenicity of BMI2012 Against COVID-19 Variant in Healthy Adults Aged 19 and 55 Years

2026年8月26日 更新者:BMI Korea

A Phase I, Multi-center, Dose Escalation, Double-blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the BMI2012 Against COVID-19 Variant in Healthy Adults Between 19 and 55 Years of Age

This Phase 1, multi-center, randomized, double-blind, placebo-controlled, dose-escalation study evaluates the safety, tolerability, and immunogenicity of BMI2012, a self-amplifying RNA vaccine candidate targeting the SARS-CoV-2 Omicron JN .1 variant, in healthy adults aged 19 to 55 years.

Participants will be enrolled sequentially into three ascending-dose cohorts and randomized within each cohort to receive a single intramuscular injection of BMI2012 or placebo. A sentinel dosing strategy with staggered administration will be used to monitor safety before enrollment of the remaining participants in each dose cohort. A Data Safety Monitoring Board (DSMB) will review safety data to determine whether enrollment may continue and to assess dose levels appropriate for further clinical development.

The primary objective is to assess the safety and tolerability of BMI2012 across the dose levels studied. Secondary objectives include exploratory evaluation of humoral and cell-mediated immune responses to BMI2012 through 52 weeks after vaccination.

研究概览

研究类型

介入性

注册 (估计的)

72

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Seoul、韩国
        • Korea University Guro Hospital
        • 接触:
        • 首席研究员:
          • Joon Young Song, MD, PhD
      • Seoul、韩国
        • Hallym University Kangnam St.Heart Hospital
        • 接触:
        • 首席研究员:
          • Jae Gab Lee, MD, PhD
      • Suwon、韩国
        • Ajou University Medical Center
        • 接触:
        • 首席研究员:
          • Jung Yeon Heo, MD, PhD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

是的

描述

[Inclusion Criteria]

  • Male and female, aged 19 to 55 years, who voluntarily decides to participate in this study and provides written informed consent
  • Meets at least one of the following:
  • (1) At least 3 months have elapsed since the last COVID-19 vaccine administration
  • (2)At least 3 months have elapsed since a confirmed diagnosis of COVID-19
  • Subjects with a body mass index (BMI) between 18kg/m² and 30 kg/m², inclusive at the screening visit
  • Male and female subjects of reproductive potential who have been using a highly effective method of contraception from at least 14 days prior to the screening visit and agree to continue using a highly effective method of contraception** up to 12 weeks after IP administration *Male subjects: Sexual abstinence, or the use of a condom, with the partner of reproductive potential using a highly effective method of contraception** *Female subjects: Use of a highly effective method of contraception**

    • Highly effective methods of contraception are as follows:
  • Hormonal contraception associated with inhibition of ovulation
  • Intrauterine device (IUD)
  • Intrauterine hormone-releasing system (IUS)
  • Bilateral tubal occlusion
  • Bilateral tubal ligation
  • Bilateral tubal resection/salpingectomy
  • Vasectomized partner
  • Sexual abstinence
  • Subjects who agree not to donate or receive blood (including whole blood, plasma, platelets, or platelet-rich plasma) during the study period
  • Subjects who have received and understood a detailed explanation of the study and voluntarily decide to participate in the study and provide written informed consent
  • Subjects who are able to comply with all visit procedures, including telephone visits, throughout the study period

[Exclusion Criteria]

  • Subjects with a positive rapid antigen test result for COVID-19 at screening
  • Subjects currently receiving an approved medicinal product for the treatment or prevention of COVID-19
  • Subjects who have had close contact with a person infected with COVID-19, or who have been classified as a confirmed or suspected case of COVID-19, within 14 days prior to IP administration
  • Healthcare professionals who may have direct involvement in care of patients confirmed with COVID-19
  • Subjects with clinically significant abnormal findings on clinical laboratory tests, electrocardiogram (ECG), or chest X-ray performed at the screening visit
  • Subjects with a positive result for any of the following at screening: HIV test, hepatitis B test, or hepatitis C test
  • Subjects who had an acute febrile illness with a body temperature of 38°C or higher within 72 hours prior to IP administration, or who are suspected of having another related infectious disease, or who had symptoms due to another infectious disease (such as cough, dyspnea, chills, myalgia, headache, sore throat, anosmia, or ageusia) within the same period
  • Subjects judged by the investigator to be unable to participate due to any of the following serious medical or psychiatric conditions:
  • (1) Respiratory disease: Asthma, chronic obstructive pulmonary disease (COPD), active tuberculosis, latent tuberculosis under treatment, or other respiratory diseases requiring daily medication; or subjects who have received treatment for exacerbation of the above respiratory diseases within 5 years prior to IP administration
  • (2) Serious cardiovascular disease: Congestive heart failure, coronary artery disease, myocardial infarction, uncontrolled hypertension, thrombocytopenic or venous thrombosis, capillary leak syndrome, myocarditis, pericarditis, etc.
  • (3) Neurological disease: Epilepsy, seizure disorder (within 3 years prior to IP administration), migraine, stroke, encephalopathy, Guillain-Barré syndrome, encephalomyelitis, transverse myelitis, etc.
  • (4) History of malignancy within 5 years prior to IP administration (excluding basal cell carcinoma and squamous cell carcinoma of the skin)
  • (5) Autoimmune disease, including autoimmune hypothyroidism and psoriasis
  • (6) Immunodeficiency disease
  • (7) Uncontrolled diabetes mellitus despite appropriate treatment ( HbA1c > 7% at screening)
  • (8) A history of dependent use of psychotropic drugs or narcotic analgesics within 24 weeks prior to IP administration, or a psychiatric condition or social circumstance that, in the Investigator's judgment, would make it difficult for the subject to comply with study procedures
  • (9) any other hepatobiliary, renal, endocrine, urinary, or musculoskeletal disease judged by the Investigator to be clinically significant
  • Subjects with a history of splenectomy
  • Subjects with a history of prior infection with SARS-CoV-1 or MERS-CoV
  • Subjects with a history of allergy or hypersensitivity to any component of the IP
  • Subjects with a history of a SAE, allergy, or hypersensitivity related to vaccination
  • Subjects with a history of generalized urticaria within 5 years prior to IP administration
  • Subjects with a history of a platelet-related disorder or bleeding disorder, or a history of significant bleeding or bruising following intramuscular injection or venipuncture, or subjects receiving anticoagulant therapy (however, subjects taking low-dose aspirin [≤100 mg/day] may be enrolled at the Investigator's judgment)
  • Subjects with a history of hereditary or idiopathic angioedema
  • Subjects with a history of organ or bone marrow transplantation
  • Subjects with suspected or a history of drug abuse or alcohol abuse within 6 months prior to IP administration
  • Subjects who have used immunosuppressants or chronic steroids within 6 months prior to IP administration (however, the use of topical, intranasal, or inhaled steroids is permitted)
  • (1) Immunosuppressants: Azathioprine, Cyclosporine, Interferon, G-CSF, Tacrolimus, Everolimus, Sirolimus, Cyclophosphamide, 6-Mercaptopurine, Methotrexate, Rapamycin, Leflunomide, etc.
  • (2) Chronic steroid use: Use of a dose exceeding 10mg/day (prednisolone equivalent) for more than 14 consecutive days
  • Subjects who have received another investigational product or been treated with another investigational medical device within 6 months prior to the screening visit
  • Subjects who are currently participating, or planning to participate, in another clinical study (including the follow-up period of an interventional study)
  • Subjects who have received or plan to receive a vaccine within 28 days before or after IP administration (however, as an exception, influenza vaccination is permitted for subjects in the non-Sentinel group if administered at least 2 weeks prior to IP administration)
  • Subjects who have received immunoglobulin or a blood product transfusion within 12 weeks prior to IP administration
  • Subjects with a scheduled surgery during the study period
  • Subjects with a positive pregnancy test result
  • Pregnant or breastfeeding women
  • Subjects judged by the Investigator to be otherwise unsuitable for participation in this study for any other reason

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Low-dose treatment
Self-amplifying RNA vaccine encoding the SARS-CoV-2 (Omicron JN.1) spike protein. Administered as a single low-dose intramuscular injection at Visit 2
安慰剂比较:Low-dose placebo control
Normal saline solution administered as a single intramuscular injection at visit 2, volume-matched to BMI2012 low-dose
实验性的:Mid-dose treatment
Self-amplifying RNA vaccine encoding the SARS-CoV-2 (Omicron JN.1) spike protein. Administered as a single mid-dose intramuscular injection at Visit 2
安慰剂比较:Mid-dose placebo control
Normal saline solution administered as a single intramuscular injection at visit 2, volume-matched to BMI2012 mid-dose
实验性的:High-dose treatment
Self-amplifying RNA vaccine encoding the SARS-CoV-2 (Omicron JN.1) spike protein. Administered as a single high-dose intramuscular injection at Visit 2
安慰剂比较:High-dose placebo control
Normal saline solution administered as a single intramuscular injection at visit 2, volume-matched to BMI2012 high-dose

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Incidence of Adverse Events Following Investigational Product Administration
大体时间:From administration through Day 28
From administration through Day 28

次要结果测量

结果测量
措施说明
大体时间
Incidence of Long-Term SAEs, MAAEs, and AESIs
大体时间:From administration through Week 52
From administration through Week 52
Clinical Safety Assessments
大体时间:From baseline through the last scheduled clinical safety assessment
Clinical laboratory test results, vital signs, physical examination findings, and ECG findings will be assessed after administration of BMI2012 or placebo
From baseline through the last scheduled clinical safety assessment
Humoral and Cell-Mediated Immune Response to BMI2012
大体时间:Day 28, Week 26, and Week 52 after administration
Day 28, Week 26, and Week 52 after administration

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2027年12月31日

研究注册日期

首次提交

2026年8月25日

首先提交符合 QC 标准的

2026年8月25日

首次发布 (实际的)

2026年8月27日

研究记录更新

最后更新发布 (实际的)

2026年8月28日

上次提交的符合 QC 标准的更新

2026年8月26日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅